Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Monolitum

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 86Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case
    Top US Lawyer Urges SCOTUS To Toss Amarin 's Label' Case

    27 Feb 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/scotus-weighs-skinny-labels-top-us-lawyer-calls-toss-amarin-case-over-hikmas-vascepa-generic

    FIERCE PHARMA
    27 Feb 2026
    Share Share
    Amarin Unveils 2025 Q4 And Full-Year Financials
    Amarin Unveils 2025 Q4 And Full-Year Financials

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244479/18362/en/Amarin-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Amarin Spotlights Underused CVD Therapies for American Heart
    Amarin Spotlights Underused CVD Therapies for American Heart

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242553/18362/en/This-American-Heart-Month-Amarin-Spotlights-the-Need-to-Prioritize-Proven-Widely-Available-Yet-Underutilized-Therapies-in-the-Battle-Against-Cardiovascular-Disease.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Amarin Reports Q4, FY 2025 Results, Hosts Feb. 25 Earnings Call
    Amarin Reports Q4, FY 2025 Results, Hosts Feb. 25 Earnings Call

    11 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/11/3236216/18362/en/Amarin-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Host-Conference-Call-on-February-25-2026.html

    GLOBENEWSWIRE
    11 Feb 2026
    Share Share
    SCOTUS to hear 'skinny label' case between Amarin, Hikma
    SCOTUS to hear 'skinny label' case between Amarin, Hikma

    20 Jan 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/supreme-court-agrees-review-skinny-label-battle-hikma-amarin-over-generic-vascepa

    FIERCE PHARMA
    20 Jan 2026
    Share Share
    Amarin Backs Advances in Elevated Triglyceride Therapy
    Amarin Backs Advances in Elevated Triglyceride Therapy

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216008/18362/en/Amarin-Applauds-Breakthroughs-In-Therapies-For-Patients-With-Elevated-Triglycerides-Company-s-VASCEPA-VAZKEPA-Icosapent-Ethyl-Franchise-Well-Positioned-To-Benefit-Globally-From-Bro.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.